ClinicalTrials.gg
CompletedNCT01284517PREVAIL3Updated Nov 26, 2013Results posted

Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression

A Phase 3 interventional study of Lurasidone and Placebo in Bipolar Depression, sponsored by Sumitomo Pharma America, Inc.. Completed at 75 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-11-26.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.

Enrollment
7th of 17
356 · median 348
Started
2010
the only one that year
Phase 3
11 of 17
none open now
Registered
4th of 17
by date
Lead sponsor
8 of 17
Sumitomo Pharma America, Inc.

Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 7th largest by enrollment, is the only one that started in 2010, is one of 11 in phase 3, and was the 4th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing lurasidone in Bipolar Disorder, or all of them as a file.
02

Study summary

Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression. This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective among patients with bipolar I depression.

03

Conditions studied

  • Bipolar Depression

Browse trials for

Keywords

  • Bipolar I Depression
  • Lurasidone
  • Latuda
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written and is 18 to 75 years of age inclusive.
  2. Meets criteria for bipolar I disorder, most recent episode depressed (≥ 4 weeks and less than 12 months) without psychotic features.
  3. Has a lifetime history of at least one bipolar manic or mixed manic episode.
  4. Currently being treated with lithium or divalproex or willing to begin treatment with lithium or divalproex.
  5. Not pregnant or nursing and is not planning pregnancy within the projected duration of the study.
  6. Females of agree to remain abstinent or use adequate and reliable throughout the study and for at least 30 days after
  7. Good physical health on the basis of medical history, physical examination, and laboratory screening.

Exclusion criteria

Exclusion Criteria:

  1. Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
  2. Any chronic organic disease of the CNS (other than Bipolar I Disorder).
  3. Hospitalization for a manic or mixed episode within the past two months.
  4. Used compound within past 6 months.
  5. history of alcohol or substance abuse within the past 3 months or alcohol or substance dependence within the past 12 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
356 participants (actual)

Study arms

  • Experimental
    Lurasidone 20-120 mg flexible dose

    Drug: Lurasidone

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Tablets 20-120 mg, PM dosing,daily for 6 weeks

    Also known as: Latuda

  • DrugPlacebo

    Equivalent to Lurasidone dosing

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)

    MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

    Time frame: Baseline to week 6

Secondary outcomes

  1. Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)

    CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

    Time frame: Baseline to week 6

  2. Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score

    SDS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

    Time frame: Baseline to week 6

07

Results

Posted Oct 14, 2013

Participant flow

Participant flow — Overall Study
MilestoneLurasidone 20-120 mg Flexible Dose+Li/VPAPlacebo + Li/VPA
Started180176
Completed148140
Not completed3236

Outcome measures

PrimaryMean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)

MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

Time frame:
Baseline to week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)
units on a scaleLurasidone 20-120 mg Flexible Dose+Li/VPAPlacebo + Li/VPA
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)-11.8 ± 0.76-10.4 ± 0.79
Statistical analysis
  • Lurasidone 20-120 mg Flexible Dose+Li/VPA vs Placebo + Li/VPA · Mixed Models Analysis · p = 0.176 · Mean difference (final values): -1.5
SecondaryMean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)

CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

Time frame:
Baseline to week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)
units on a scaleLurasidone 20-120 mg Flexible Dose+Li/VPAPlacebo + Li/VPA
Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)-1.36 ± 0.099-1.13 ± 0.102
Statistical analysis
  • Lurasidone 20-120 mg Flexible Dose+Li/VPA vs Placebo + Li/VPA · Mixed Models Analysis · p = 0.095 · Mean difference (final values): -0.24
SecondaryMean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score

SDS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

Time frame:
Baseline to week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score
units on a scaleLurasidone 20-120 mg Flexible Dose+Li/VPAPlacebo + Li/VPA
Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score-5.4 ± 0.85-5.4 ± 0.74
Statistical analysis
  • Lurasidone 20-120 mg Flexible Dose+Li/VPA vs Placebo + Li/VPA · ANCOVA · p = 0.992 · Mean difference (final values): 0.0

Adverse events

Collected over 13 December 2010 to 7 August 2012. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone 20-120 mg Flexible Dose+Li/VPA—5/177 (2.8%)79/177 (44.6%)
Placebo + Li/VPA—3/171 (1.8%)63/171 (36.8%)
Most frequent serious events
Most frequent serious events
EventLurasidone 20-120 mg Flexible Dose+Li/VPAPlacebo + Li/VPA
ManiaPsychiatric disorders0/1771/171
Transient Ischemic AttackNervous system disorders0/1771/171
Flank PainMusculoskeletal and connective tissue disorders0/1771/171
DepressionPsychiatric disorders1/1770/171
Suicidal IdeationPsychiatric disorders1/1770/171
Intentional OverdoseInjury, poisoning and procedural complications1/1770/171
Anaphylactic ShockImmune system disorders1/1770/171
Disease ProgressionGeneral disorders1/1770/171
Depression SuicidalPsychiatric disorders1/1770/171
AngioedemaSkin and subcutaneous tissue disorders1/1770/171
Most frequent other events
Most frequent other events
EventLurasidone 20-120 mg Flexible Dose+Li/VPAPlacebo + Li/VPA
AkathisiaNervous system disorders25/1779/171
InsomniaPsychiatric disorders15/17718/171
NauseaGastrointestinal disorders18/17716/171
HeadacheNervous system disorders15/17715/171
SomnolenceNervous system disorders15/1775/171
DiarrhoeaGastrointestinal disorders14/17710/171
TremorNervous system disorders11/1779/171
DizzinessNervous system disorders9/1779/171

Baseline characteristics

This is the full analysis set (intent-to-treat population)

Age, Categorical
Age, Categorical(Participants)Lurasidone 20-120 mg Flexible Dose+Li/VPAPlacebo + Li/VPATotal
<=18 years303
Between 18 and 65 years166161327
>=65 years7512
Age Continuous
Age Continuous(years)Lurasidone 20-120 mg Flexible Dose+Li/VPAPlacebo + Li/VPATotal
Mean43.1 ± 11.9044.1 ± 11.9943.6 ± 11.94
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone 20-120 mg Flexible Dose+Li/VPAPlacebo + Li/VPATotal
Female9193184
Male8573158
Region of Enrollment
Region of Enrollment(participants)Lurasidone 20-120 mg Flexible Dose+Li/VPAPlacebo + Li/VPATotal
United States7163134
Czech Republic9817
Slovakia172138
Canada9817
Ukraine171431
Lithuania10919
Peru6713
Colombia121022
Japan549
India202242
08

Study locations

75 sites
  • Clinical Innovations, Inc.
    Costa Mesa, California 92647, United States
  • Clinical Innovations Inc.
    Riverside, California 92506, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92123, United States
  • Sharp Mesa Vista Hospital
    San Diego, California 92123, United States
  • Clinical Innovations inc.
    Santa Ana, California 92705, United States
  • Collaborative Neuroscience Network
    Torrance, California 90502, United States
  • Colorado Clinical Trials Inc.
    Highlands Ranch, Colorado 80130, United States
  • Accurate Clinical Trials
    Kissimmee, Florida 34741, United States
  • Clinical Neuroscience Solutions Inc.
    Orlando, Florida 32806, United States
  • Northwest Behavioral Research Center
    Roswell, Georgia 30076, United States
  • Institute for Behavioral Medicine LLC
    Smyrna, Georgia 30080, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Village Clinical Research Inc.
    New York, New York 10003, United States
  • Medical & Behavioral Health Research
    New York, New York 10023, United States
  • Zarzar Psychiatric Associates, PLLC
    Raleigh, North Carolina 27607, United States
  • Summit Research Network (Oregon) Inc.
    Portland, Oregon 97210, United States
  • Lehigh Valley Hospital
    Allentown, Pennsylvania 18103, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • FutureSearch Clinical Trials, LP
    Dallas, Texas 75231, United States
  • Pillar Clinical Research
    Dallas, Texas 75243, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • Summit Research Network (Seattle) LLC
    Seattle, Washington 98104, United States
  • Clinical Research Group Edmonton Inc
    Edmonton, Alberta T6L 6W6, Canada
  • Okanagan Clinical Trials
    Kelowna, British Columbia V1Y 1Z9, Canada
  • Pierre-Janet Hospital
    Gatineau, Quebec J9A 1K7, Canada
  • Hopital Louis-H Lafontaine
    Montreal, Quebec H1N 3M5, Canada
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA
    Barranquilla, Colombia
  • Centro de Investigacion y Atencion para la Salud Mental
    Bogota, 103, Colombia
  • CISNE - UIC Campo Abierto
    Bogota, Colombia
  • Hospital Mental de Antioquia
    Cali, Colombia
  • Psychiatricka ambulance
    Brno-mesto, 602 00, Czech Republic
  • Vojenska nemocnice Olomouc
    Olomouc, 711 11, Czech Republic
  • Clintrial, s.r.o.
    Praha, 10 100 00, Czech Republic
  • Psychiatry Trial s.r.o.
    Praha, 158 00, Czech Republic
  • Brain Mind Behavior Neuroscience Research Institute
    Vishakhapatnam, Andh Prad 530002, India
  • Shanti Nursing Home
    Kanchanpalli, Aurangabad, Maharashtra, India
  • SBKS Medical College and Hospital, Brij Psychiatry Hospital
    Vadodara, Gujarat 390001, India
  • Abhaya Hospital Psychiatry
    Bangalore, Karna 560027, India
  • K.S. Hegde Medical Academy
    Mangalore, Karna 575018, India
  • Poona Hospital & Research Center
    Pune, Mahara 411 030, India
  • Mahatma Ghandi Institute of Medical Sciences
    Wardha, Mahara 442102, India
  • Mental Health Care & Research
    Jaipur, Rajasthan 302017, India
  • R.K. Yadav Memorial Mental Health & De-addiction Hospital
    Jaipur, Rajasthan 302021, India
  • Mahendru Psychiatric Center
    Kanpur, Uttar Prad 208005, India
  • Chatrapati Shau Maharaj Medical University
    Lucknow, Utter Prad 226003, India
  • Ongata Hospital
    Hachioji-shi, 192 0153, 13, Japan
  • Kohnodai Hospital, National Center for Global Health & Medicine
    Ichikawa, 272 8516 12, Japan
  • National Hospital Organization Hizen Psychiatric Center
    Kanzaki-gun, 842 0192 41, Japan
  • National Center of Neurology & Psychiatry
    Kodaira-shi, 187 8551 13, Japan
  • Asakayama General Hospital
    Sakai-shi, 590 0018, 27, Japan
  • Osaka Institute of Clinical Psychiatry Shin-abuyama Hospital
    Takatsuki, 569-1041, Japan
  • Neuromeda JSC
    Kaunas, 50185, Lithuania
  • Ziegzdriai Mental Hospital, Public Institution
    Kaunas, 53136, Lithuania
  • Silutes Mental Health & Psychtherapy Center, JSC
    Silute, 99142, Lithuania
  • Seskines Outpatient Clinic, Public Institution
    Vilnius, 07156, Lithuania
  • Zirmunai Mental Health Center, Public Institution
    Vilnius, 09112, Lithuania
  • Hospital Nacional Arzobispo Loayza
    Lima, 01, Peru
  • Hospital Nacional Hipolito Unanue
    Lima, 27, Peru
  • Clinica Vesalio
    Lima, 41, Peru
  • Centrum zdravia R. B. K. s.r.o.
    Bardejov, 085 01, Slovakia
  • Bojniciach
    Bojnice, 97201, Slovakia
  • Psychiatricka ambulancia Mentum s.r.o.
    Bratislava, 82007, Slovakia
  • FNsP Bratislava, Nemocnica Ruzinov
    Bratislava, 82606, Slovakia
  • Nemocnica s poliklinikou Liptovsky Milulas
    Liptovsky Mikulas, 03123, Slovakia
  • PsychoLine s.r.o.
    Rimavska Sobota, 97901, Slovakia
  • Nemocnica s poliklikou Sv. Barbory
    Roznava, 048 01, Slovakia
  • Pro mente sana
    Trencin, 91101, Slovakia
  • Kherson Regional Psychiatric Hospital
    Kherson, Vil Stepanivka 73488, Ukraine
  • Dnipropetrovsk Regional Clinical Hospital named Mechnikov
    Dnipropetrovsk, 49005, Ukraine
  • Com Inst Knipropetrovsk Reg Cl Psych Hospital DSMA
    Dnipropetrovsk, 49115, Ukraine
  • St. In. Inst of Neurol, Psych, and Narcol of the AMSU
    Kharkov, Ukraine
  • Kyiv City Psychoneurological Hospital #2
    Kyiv, 02660, Ukraine
  • Lviv Regional Clinical Psychiatric Hospital
    Lviv, 79021, Ukraine
  • Ternopil Regional Municipal Dispensary, Narcology Dept.
    Ternopil, 46020, Ukraine
  • Zapor. Reg. CI Hospital, Zaporizhzhia SMU
    Zaporizhzhya, 69032, Ukraine
09

References and documents

Publications

  • Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. J Psychiatr Res. 2016 Jul;78:86-93. doi: 10.1016/j.jpsychires.2016.03.012. Epub 2016 Mar 31. PubMed 27089521 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2011
First posted
Jan 27, 2011
Start
Nov 2010
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Oct 14, 2013
Last update
Nov 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01284517
Responsible party
Sponsor
First posted
Jan 27, 2011
Start date
Nov 2010
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Oct 14, 2013
Last update
Nov 26, 2013

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion